Ovid Therapeutics (OVID) Capital Expenditures (QoQ) (2016 - 2024)
Powered by 
Analysis
Ovid Therapeutics (OVID) Capital Expenditures (QoQ) (2016 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn |
| 10 | Ovid Therapeutics | 517.32 Mn | 400.10 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 410.53% |
| Mar 31, 2024 | 246.15% |
| Jun 30, 2023 | 585.71% |
| Mar 31, 2023 | -88.33% |
| Dec 31, 2022 | 544.83% |
| Sep 30, 2022 | -98.21% |
| Jun 30, 2022 | 2,163.86% |
| Mar 31, 2022 | -71.64% |
| Dec 31, 2021 | 1,437.33% |
| Sep 30, 2021 | 1,053,400.00% |
| Jun 30, 2021 | -99.99% |
| Mar 31, 2021 | -76.31% |
| Dec 31, 2020 | 111.30% |
| Sep 30, 2020 | 666.67% |
| Jun 30, 2020 | -98.41% |
| Mar 31, 2020 | 17.31% |
| Dec 31, 2019 | 783.96% |
| Sep 30, 2019 | 497.08% |
| Jun 30, 2019 | -34.41% |
| Mar 31, 2019 | -82.81% |